A Brazilian retrospective cohort study reports that ceftazidime–avibactam regimens were independently associated with reduced 30-day mortality in carbapenem-resistant Klebsiella pneumoniae bloodstream infections compared with other active antimicrobials. The analysis frames the outcome as an effectiveness signal in real-world practice for a high-mortality pathogen. Because the study is observational, confounding by baseline severity and regimen selection remains a key limitation, but the independent association strengthens the case for targeted use of ceftazidime–avibactam in CRKP bacteremia. For antimicrobial stewardship and pipeline positioning, the result adds evidence supporting continued clinical preference for specific last-resort beta-lactam combinations.
Get the Daily Brief